Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Portfolio Pulse from Lisa Levin
Insiders have recently made significant purchases in three penny stocks: Diversified Healthcare Trust (DHC), TScan Therapeutics (TCRX), and Athira Pharma (ATHA). DHC posted a profit for Q1, TCRX received FDA clearance for an investigational new drug application, and Mizuho maintained a Buy rating on ATHA with a lowered price target.
June 07, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Athira Pharma's Andrew Gengos acquired 65,012 shares at an average price of $2.95, costing around $191.57 thousand. Mizuho maintained a Buy rating on the company with a lowered price target.
The insider purchase by Andrew Gengos, along with Mizuho maintaining a Buy rating on the company, indicates confidence in the company's prospects despite the lowered price target. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Diversified Healthcare Trust's director acquired 5,566,644 shares at an average price of $1.77, costing around $9.81 million. The company posted a profit for Q1.
The significant insider purchase by the director indicates confidence in the company's prospects, especially after posting a profit for Q1. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
TScan Therapeutics' director acquired 37,880 shares at an average price of $2.63, costing around $99.56 thousand. The company announced FDA clearance of an investigational new drug application.
The insider purchase by the director, along with the FDA clearance of an investigational new drug application, indicates confidence in the company's prospects. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100